A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate.

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2016

At a glance

  • Drugs Brodalumab (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 14 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 11 Nov 2012 Primary endpoint 'American-College-of-Rheumatology-50%-response-criteria' has not been met.
    • 14 Apr 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top